PRO‐C3 levels were significantly different in both the S2–4 group and S3–4 group as compared with the group with lower staged fibrosis (Table 1), with the median value of PRO‐C3 significantly lower in S0–1 as compared with S2–4 patients (16.26 [11.38–42.01] ng/mL vs. 41.64 [22.50–59.94] ng/mL, p < 0.001) and in S0–2 as compared with S3–4 patients (19.51 [12.14–35.70] ng/mL vs. 50.82 [33.88–66.96] ng/mL, p < 0.001). This evidence concerns the gene C3 and fibrosis.